IV nurse promoting peptide therapy on TikTok: fact check

What did @ivnursejen actually say?

The argument here is a comparison, not a safety claim. @ivnursejen points to FDA-authorized flavored e-cigarettes and asks why peptides don't get the same treatment. Her conclusion: "it's not about product, it's about money." She ends with sarcasm, telling viewers to "do e-cigarettes instead" of peptides.

To be clear, this is a rhetorical move, not a clinical argument. She's not explaining what peptides do, what risks they carry, or what the approval process actually requires. The video is about regulatory distrust, and it's worth taking that seriously, even if the specific comparison she makes doesn't hold up to scrutiny.

Does the science back this up?

The FDA approval comparison is the wrong frame here. The FDA has multiple approval pathways, and they evaluate vastly different product categories under different legal standards. Comparing e-cigarette authorization to peptide approval isn't apples and oranges, it's apples and a car.

FDA authorized certain flavored e-cigarettes under the Premarket Tobacco Product Application (PMTA) pathway, which weighs "appropriate for the protection of public health" against existing tobacco use, not against zero risk. Peptides like BPC-157, TB-500, and CJC-1295 are biologics or small-molecule compounds that would require Investigational New Drug (IND) applications, Phase I-III clinical trials, and biologics license applications. The data infrastructure simply doesn't exist yet. Budge et al. (2022, Regulatory Toxicology and Pharmacology) noted that many research peptides lack even basic Phase I human safety data. That's the gap, not a conspiracy.

What did they get wrong (or right)?

She got the frustration right. FDA approval timelines are slow, expensive, and often shaped by who can afford to run trials. That's a documented reality, not a fringe opinion. A 2019 analysis by Wouters et al. in JAMA Internal Medicine found that drug development costs create structural barriers that systematically favor high-revenue drugs over compounds with limited commercial upside. Peptides, many of which can't be patented, face exactly this problem.

But the e-cigarette comparison is misleading in a way that matters. Flavored e-cigarettes weren't approved because they're safe, they were authorized under a harm-reduction calculus specific to tobacco regulation. Using that as evidence that the FDA rewards money over safety gets the mechanism backwards. Several flavored products were also denied authorization. The implication that peptides are being blocked while dangerous products sail through misrepresents how both pathways work. That's worth correcting plainly.

What should you actually know?

The lack of FDA approval for most research peptides isn't proof of suppression, but it's also not proof they're unsafe or ineffective. It means independent, large-scale human trial data is largely absent. For some compounds, the preclinical data is genuinely interesting. For others, the hype is well ahead of the evidence.

BPC-157, for example, has a substantial body of animal research, including work by Sikiric et al. published across multiple years in Current Pharmaceutical Design, but human RCT data remains sparse. GHK-Cu has published mechanistic data on wound healing and skin remodeling (Pickart et al., 2015, Journal of Aging Science), but clinical endpoints in humans are limited. The honest answer is that "not FDA approved" tells you about regulatory status, not about whether something works or is safe for you specifically. Those are different questions, and conflating them, in either direction, doesn't serve patients.

• Compounded peptides sourced outside licensed pharmacies carry real contamination and dosing risks that the e-cigarette comparison completely ignores.
• If you're considering peptide therapy, that conversation belongs with a licensed clinician who can review your health history, not a TikTok comment section.